Centene Corp (CNC)

Investment Committee Summary

Investment Thesis

At $65.65 (25 August 2026) Centene trades on roughly 18x forward earnings, a discount to the managed-care peer median, and on an enterprise value that is a small fraction of its premium revenue base. The market is pricing a partial margin recovery: it accepts that the loss year is behind the company, but not that a mid-cycle margin returns durably. The operating line currently earns close to 1.2%, so every point of medical-cost trend matters enormously. The engine's cash-flow and peer-multiple measures argue the equity is worth more than the tape allows, but the scenario tree pulls the blend back — more than a third of the probability sits in cost-trend or reform states where earnings compress hard. What lands is a triangulated fair value of $60.87; the shares are fairly valued against it, a gap of -7%, with the probability-weighted expected value at $64.05 and the twelve-month target set from it at $64.08. The balance sheet carries net cash of ~$4.9B, which provides some buffer. The HOLD rating follows: the measures argue cheap, the tree argues fragile, and the two net out. The single most damaging risk is Medicaid rate inadequacy compounding with federal reform, which drives the structural target below the 52-week low.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($65.65) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The steelman bear is structural, not cyclical. Centene's book is concentrated in government lines whose economics are set by legislators rather than by underwriting skill. Redeterminations have already stripped healthier members; if enhanced exchange subsidies lapse and Medicaid work requirements bite, the residual pool's acuity rises while the premium base shrinks, so margin and revenue fall together. The prior year's reported net loss shows how violently a margin as thin as 1.2% swings when trend is mispriced for even one rate cycle. In that state earnings power settles far below the base path, the market pays a distressed multiple for a policy-exposed book, and the structural target sits below the 52-week low. Nothing in that chain requires management error; it requires only that policy moves against the book, and there is no pricing lever that works inside a single rate cycle.

Key Debate

Gross Margin explains 83% of Monte Carlo outcome variance — the single variable that decides which side is right.

What the Market Is Pricing In

At the current price, the market pays 13.4× consensus forward EPS, vs the house DCF terminal 15.0×, and a peer median 22.2×. The house DCF sits 59% above spot, so the market is pricing in less than the house case — roughly 7.5pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Medicare/Medicaid Reform / MLR Squeeze' downside ($21.40) to a 'Bull — Margin Recovery / Re-Rate' bull case ($116); the probability-weighted blend (PWEV $64.05) is -2% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 0.1% of revenue; free cash flow net of SBC is $4.12B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Medicare/Medicaid Reform / MLR Squeeze (20%, $21.40). Structural impairment — Medicare/Medicaid reform / MLR squeeze: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Cost-Trend Spike / Rate Inadequacy (17%, $49.10). Cyclical downturn — membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy weakens for 1–2 years before normalising.
• Base — Membership + Premium Growth (35%, $67.90). Mid-cycle — normalised membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy; disciplined capital allocation; steady returns.
• Growth — MA / Care-Services (Optum-style) (20%, $91.90). Upside — MA + care-services growth lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Margin Recovery / Re-Rate (8%, $116). Upside tail — sustained tight conditions or a structural re-rate on MA + care-services growth.

Valuation Triangulation

Two weighted anchors — a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat two numbers as two independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name DCF, sum-of-parts, peer P/E re-rate are not computed, so 60% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

DCF excluded from the weighted blend — diverges >55% from the Monte-Carlo / scenario core. For a high-leverage equity the per-share DCF (enterprise value less large net debt) is hypersensitive to the terminal multiple; a peer re-rate across heterogeneous margins is apples-to-oranges. Shown above for reference; the blend leans on the multiple-discipline and scenario anchors.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $55.57 and 42% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (83% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 15.0x terminal FCF multiple → $105. Excluded from the weighted blend as an outlier — retained as an independent cross-check on the multiple-driven anchors.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $199; the peer-median forward P/E is 22.2x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 137% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Managed Care / Health Services multiple (AI re-rating) (base 18.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 20.8× (simple median 22.2×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $25.08–$68.72, centre $41.50 (-37% vs spot); spot sits at the 93rd percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Margin Recovery / Re-Rate): $116.

Company Overview & Business Model

Centene Corp — HEALTHCARE · HEALTHCARE PLANS. Centene Corporation is a large publicly traded company and a multi-line managed care enterprise that serves as a major intermediary for both government-sponsored and privately insured health care programs. It is a healthcare insurer that focuses on managed care for uninsured, underinsured, and low-income individuals.

How it makes money.

Edge. Narrow moat. Authored moat rationale withheld pending re-authoring.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue.

Competitive Moat

Moat sources:

• Scale in government-sponsored (Medicaid/CHIP/Marketplace/MA) managed care with state-contract incumbency
• Provider-network breadth and state relationships raising re-procurement switching friction
• Weakness: MLR / rates set by regulators and states — limited independent pricing power
• Weakness: contract concentration risk on periodic Medicaid re-bids

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.43 vs analyst floor +0.00 → delta +0.43 (n=20 mgmt / 12 Q&A; 55th pctile across the S&P book, z +0.1).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1302 articles): avg ticker sentiment +0.11 (bullish 18% / bearish 7%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-05 (~42d) — 2027 Medicare Advantage Star-ratings and bid results (authored)
• 2026-10-27 (~64d) — Quarterly earnings — est. EPS $0.05 (AV EARNINGS_CALENDAR)
• 2026-12-15 (~113d) — 2027 Medicaid rate-cycle / state redetermination true-up outcomes (authored)
• 2027-01-31 (~160d) — FY2027 EPS guidance / margin-recovery framework at Q4 update (authored)

Forecast Track Record

• EPS surprise: beat 88% of the last 8 quarters; average surprise +71.5%.
• Prior-forecast backtest (12 snapshots, 2026-06-27→2026-08-20): directional hit-rate 75%; mean predicted -0.9% vs realised +1.5%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

6 catalysts in the next 90 days (of 16 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Scenario-macro rows withheld pending re-authoring: 1 carrying another cluster's vocabulary or a frozen figure — recorded in the narrative quarantine ledger.

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 5 evaluable (1 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Consolidated health benefits ratio (HBR/MLR) > 0.915 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• FY adjusted EPS guidance < 3.5 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
• Medicaid managed-care membership < 12.5 (2 consecutive prints). Membership (millions) sustained below 12.5m signals redetermination and reform attrition beyond contract-exit plans, cutting the premium base that carries the fixed-cost load and validating the structural-reform mechanism.
• ACA marketplace (Ambetter) enrolment < 4.0 (2 consecutive prints). Enrolment (millions) sustained below 4.0m indicates the lapse of enhanced subsidies is stripping out the healthiest cohort, worsening residual-pool acuity and the HBR simultaneously — the exact structural-scenario mechanism.
• Full-year premium and service revenue guidance < 185.0 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $65.65; 52-week range $25.08–$68.72; engine rating HOLD; house target $64.08 (-2%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $60.87 (-7% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits above the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

57.5/100 (confidence band 44.4–70.6), 48th percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 57.1 → 57.1 → 55.3 → 57.5 → 57.5 → 55.4 → 57.6 → 57.6.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $64.05.

Flagged for review: internal coherence (authored mass vs Monte Carlo). A flag marks a disagreement worth understanding — it does not imply either side is wrong.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.07, vs QQQ +0.02 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Covered Call. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• range-bound with fair premium — harvest income against a holding
• Direction neutral from the overlay conviction/rating (read-only input).
• IV/RV at the 61st percentile of the cross-section → mid vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 67th percentile of its own month-end history (decile 7). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.
• IV term structure is in contango (longer-dated richer, slope +5.8pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.

IV term structure (contango, slope +5.8pp): 32-DTE 39% · 88-DTE 45% · 389-DTE 44%

Economics copied verbatim from the options overlay (priced from the listed chain (EOD marks)); the selector does not re-price.

Alternatives: Cash-Secured Put. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the HOLD equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 38.6% (moderate regime) · expected move ±9.2% (2026-09-25) · put/call OI 0.40 · ATM Δ 0.52 / Θ -0.05 / ν 0.08 · next earnings 2026-10-27. Direction: NEUTRAL (implied return -7.3% to triangulated fair value $60.87).

Covered Call (if held) (Income / neutral) — Short 70 C · 2026-09-25 · premium $1.67 · yield 2.5% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 60 P / Long 56 P · 2026-10-02 · net $0.44 · net entry $59.55 · yield 0.7% · RoR 13.0% · max loss $3.56 · priced from the listed chain (EOD marks)

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put.

Protective Collar (if held) (Hedge) — Long 60 P / Short 72.5 C · 2027-03-19 · net $1.25 · floor -9.0% · cap +10.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -2% vs spot
• Monte Carlo median implies -15% vs spot
• DCF fair value implies +59% vs spot
• Bear case (Structural — Medicare/Medicaid Reform / MLR Squeeze) downside is -67% vs spot
• Net: the valuation anchor itself sits 7.3% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 2% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $12B + PV(terminal) $35B = EV $47B; + net cash $4.9B → equity $52B ÷ diluted shares $0.50B = $105/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $114/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 15% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $199 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (299.0); Revenue CAGR ±3pp (25.0); Terminal × ±15% (21.0); Capex intensity ±15% (9.0); WACC ±1pp (8.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 15×, FY+5 revenue $241B. Triangulation leans 62% on PWEV, 37% on the Monte Carlo median.